Plasma Drug Testing for D and L Isomers of Amphetamine and Methamphetamine by Liquid Chromatography Mass Spectrometry with a Range of 2.5 to 1000 ng/mL
Authors
Carpenter, R., Long, M., Robbins, B.
Publication date
January 2023
Journal
International Journal of Laboratory Hematology
Volume
45
Pages
29
Publisher
Wiley
Description
Introduction: Development and validation of a quantitative plasma assay for measuring D and L amphetamine and methamphetamine in human K2 EDTA samples to determine prescription versus illicit sources of the analytes. The assay was developed using liquid-liquid extraction followed by a dry down step and reconstitution with D and L mobile phase. The samples were separated on a chiral column and measured using an API 4000™ LC/MS/MS system.
Methods: The assay was validated according to US FDA, CLIA and CAP guidelines including assessment of the following parameters in plasma validation samples: linear range, limit of detection, lower limit of quantitation, matrix effects, inter- and intra-day assay precision and accuracy, carry over, linearity of dilution, matrix effects and stability. Detection was done by using an The assay was validated according to US FDA, CLIA and CAP guidelines including assessment of the following parameters in plasma validation samples: linear range, limit of detection, lower limit of quantitation, matrix effects, inter- and intra-day assay precision and accuracy, carry over, linearity of dilution, matrix effects and stability. Detection was done by using an API 4000™ LC/MS/MS system. The chiral separation was performed using isocratic separation with a Supelco Astec CHIROBIOTIC® V2 (25 cm x 2.1 mm, 5μm) column.
Methods: The assay was validated according to US FDA, CLIA and CAP guidelines including assessment of the following parameters in plasma validation samples: linear range, limit of detection, lower limit of quantitation, matrix effects, inter- and intra-day assay precision and accuracy, carry over, linearity of dilution, matrix effects and stability. Detection was done by using an The assay was validated according to US FDA, CLIA and CAP guidelines including assessment of the following parameters in plasma validation samples: linear range, limit of detection, lower limit of quantitation, matrix effects, inter- and intra-day assay precision and accuracy, carry over, linearity of dilution, matrix effects and stability. Detection was done by using an API 4000™ LC/MS/MS system. The chiral separation was performed using isocratic separation with a Supelco Astec CHIROBIOTIC® V2 (25 cm x 2.1 mm, 5μm) column.